Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir/Velpatasvir/Voxilaprevir: A Multicenter Real-World Experience from Türkiye
The combination of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) is recommended as a salvage therapy for treatment-experienced chronic hepatitis C (CHC) patients. However, it is used in our country for treatment-naïve and treatment-experienced patients. This study aims to present real-world data...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/17/7/931 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849251852582912000 |
|---|---|
| author | Umut Devrim Binay Faruk Karakeçili Bilgehan Aygen Ayşin Kılınç Toker İlhami Çelik Neşe Demirtürk Tuğçe Şimşek Bozok Leyla Dursun Fethiye Akgül Güle Çınar Özgür Günal Ali Asan Eyüp Arslan Fatma Yılmaz Karadağ Orçun Barkay İrem Akdemir Funda Şimşek Emine Türkoğlu Yılmaz Zeynep Ravza Eğilmez Süda Tekin The Viral Hepatitis Study Group of the Turkish Society of Clinical Microbiology and Infectious Diseases (KLİMİK) |
| author_facet | Umut Devrim Binay Faruk Karakeçili Bilgehan Aygen Ayşin Kılınç Toker İlhami Çelik Neşe Demirtürk Tuğçe Şimşek Bozok Leyla Dursun Fethiye Akgül Güle Çınar Özgür Günal Ali Asan Eyüp Arslan Fatma Yılmaz Karadağ Orçun Barkay İrem Akdemir Funda Şimşek Emine Türkoğlu Yılmaz Zeynep Ravza Eğilmez Süda Tekin The Viral Hepatitis Study Group of the Turkish Society of Clinical Microbiology and Infectious Diseases (KLİMİK) |
| author_sort | Umut Devrim Binay |
| collection | DOAJ |
| description | The combination of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) is recommended as a salvage therapy for treatment-experienced chronic hepatitis C (CHC) patients. However, it is used in our country for treatment-naïve and treatment-experienced patients. This study aims to present real-world data from Türkiye on CHC patients treated with SOF/VEL/VOX. The present study was conducted by the Viral Hepatitis Study Group of the Turkish Society of Clinical Microbiology and Infectious Diseases (KLİMİK). It was a multicenter, retrospective, observational study. The data were collected from patients receiving SOF/VEL/VOX therapy at 12 medical centers in Türkiye between 1 June 2022 and 31 December 2024. The patients had received the treatment for 8 to 12 weeks. Of the 139 patients enrolled, 63.3% (<i>n</i> = 88) were male, with a mean age of 54.4 years. Most patients were non-cirrhotic (94.2%, <i>n</i> = 131) and treatment-naïve (92%, <i>n</i> = 128); 49.6% (<i>n</i> = 69) were infected with genotype 1b. Early virologic response (EVR) could be assessed in 126 patients, with an EVR rate of 82.5% (<i>n</i> = 104). End-of-treatment data were available for 113 patients, all achieving an end-of-treatment response. Among the 80 patients for whom week-12 post-treatment data were available, 97.5% sustained virologic response at week 12 (SVR12). Significant improvements were observed in AST, ALT, and platelet levels, along with reductions in APRI and FIB-4 scores (<i>p</i> = 0.001).” No serious adverse events leading to treatment discontinuation were reported. Mild adverse events included pruritus (2.1%, <i>n</i> = 3), fatigue (2.1%, <i>n</i> = 3), and nausea (1.4%, <i>n</i> = 2). The SOF/VEL/VOX combination is a highly effective and well-tolerated treatment option in treatment-naïve CHC patients, achieving an SVR12 rate of 97.5%. |
| format | Article |
| id | doaj-art-3e21eaa45d1b44059619230df3e23f8b |
| institution | Kabale University |
| issn | 1999-4915 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj-art-3e21eaa45d1b44059619230df3e23f8b2025-08-20T03:56:49ZengMDPI AGViruses1999-49152025-06-0117793110.3390/v17070931Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir/Velpatasvir/Voxilaprevir: A Multicenter Real-World Experience from TürkiyeUmut Devrim Binay0Faruk Karakeçili1Bilgehan Aygen2Ayşin Kılınç Toker3İlhami Çelik4Neşe Demirtürk5Tuğçe Şimşek Bozok6Leyla Dursun7Fethiye Akgül8Güle Çınar9Özgür Günal10Ali Asan11Eyüp Arslan12Fatma Yılmaz Karadağ13Orçun Barkay14İrem Akdemir15Funda Şimşek16Emine Türkoğlu Yılmaz17Zeynep Ravza Eğilmez18Süda Tekin19The Viral Hepatitis Study Group of the Turkish Society of Clinical Microbiology and Infectious Diseases (KLİMİK)Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erzincan Binali Yıldırım University, 24100 Erzincan, TürkiyeDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erzincan Binali Yıldırım University, 24100 Erzincan, TürkiyeDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erciyes University, 38030 Kayseri, TürkiyeDepartment of Infectious Diseases and Clinical Microbiology, Kayseri City Hospital, University of Health Sciences, 38080 Kayseri, TürkiyeDepartment of Infectious Diseases and Clinical Microbiology, Kayseri City Hospital, University of Health Sciences, 38080 Kayseri, TürkiyeDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Afyonkarahisar Health Sciences University, 03030 Afyonkarahisar, TürkiyeDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Mersin University, 33343 Mersin, TürkiyeDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erciyes University, 38030 Kayseri, TürkiyeDepartment of Infectious Diseases and Clinical Microbiology, Batman Training and Research Hospital, 72070 Batman, TürkiyeDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ankara University, 06230 Ankara, TürkiyeDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Samsun University, 55080 Samsun, TürkiyeDepartment of Infectious Diseases and Clinical Microbiology, Bursa Yüksek İhtisas Training and Research Hospital, University of Health Sciences, 16310 Bursa, TürkiyeDepartment of Infectious Diseases and Clinical Microbiology, Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, University of Health Sciences, 34785 İstanbul, TürkiyeDepartment of Infectious Diseases and Clinical Microbiology, Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, University of Health Sciences, 34785 İstanbul, TürkiyeDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erzincan Binali Yıldırım University, 24100 Erzincan, TürkiyeDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ankara University, 06230 Ankara, TürkiyeDepartment of Infectious Diseases and Clinical Microbiology, Prof. Dr. Cemil Taşçıoğlu City Hospital, University of Health Sciences, 34384 İstanbul, TürkiyeDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Tokat Gaziosmanpaşa University, 60030 Tokat, TürkiyeDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erciyes University, 38030 Kayseri, TürkiyeDepartment of Infectious Diseases and Clinical Microbiology, Acıbadem Ataşehir Hospital, 34642 İstanbul, TürkiyeThe combination of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) is recommended as a salvage therapy for treatment-experienced chronic hepatitis C (CHC) patients. However, it is used in our country for treatment-naïve and treatment-experienced patients. This study aims to present real-world data from Türkiye on CHC patients treated with SOF/VEL/VOX. The present study was conducted by the Viral Hepatitis Study Group of the Turkish Society of Clinical Microbiology and Infectious Diseases (KLİMİK). It was a multicenter, retrospective, observational study. The data were collected from patients receiving SOF/VEL/VOX therapy at 12 medical centers in Türkiye between 1 June 2022 and 31 December 2024. The patients had received the treatment for 8 to 12 weeks. Of the 139 patients enrolled, 63.3% (<i>n</i> = 88) were male, with a mean age of 54.4 years. Most patients were non-cirrhotic (94.2%, <i>n</i> = 131) and treatment-naïve (92%, <i>n</i> = 128); 49.6% (<i>n</i> = 69) were infected with genotype 1b. Early virologic response (EVR) could be assessed in 126 patients, with an EVR rate of 82.5% (<i>n</i> = 104). End-of-treatment data were available for 113 patients, all achieving an end-of-treatment response. Among the 80 patients for whom week-12 post-treatment data were available, 97.5% sustained virologic response at week 12 (SVR12). Significant improvements were observed in AST, ALT, and platelet levels, along with reductions in APRI and FIB-4 scores (<i>p</i> = 0.001).” No serious adverse events leading to treatment discontinuation were reported. Mild adverse events included pruritus (2.1%, <i>n</i> = 3), fatigue (2.1%, <i>n</i> = 3), and nausea (1.4%, <i>n</i> = 2). The SOF/VEL/VOX combination is a highly effective and well-tolerated treatment option in treatment-naïve CHC patients, achieving an SVR12 rate of 97.5%.https://www.mdpi.com/1999-4915/17/7/931sofosbuvir/velpatasvir/voxilaprevirhepatitis C treatmentreal-world data |
| spellingShingle | Umut Devrim Binay Faruk Karakeçili Bilgehan Aygen Ayşin Kılınç Toker İlhami Çelik Neşe Demirtürk Tuğçe Şimşek Bozok Leyla Dursun Fethiye Akgül Güle Çınar Özgür Günal Ali Asan Eyüp Arslan Fatma Yılmaz Karadağ Orçun Barkay İrem Akdemir Funda Şimşek Emine Türkoğlu Yılmaz Zeynep Ravza Eğilmez Süda Tekin The Viral Hepatitis Study Group of the Turkish Society of Clinical Microbiology and Infectious Diseases (KLİMİK) Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir/Velpatasvir/Voxilaprevir: A Multicenter Real-World Experience from Türkiye Viruses sofosbuvir/velpatasvir/voxilaprevir hepatitis C treatment real-world data |
| title | Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir/Velpatasvir/Voxilaprevir: A Multicenter Real-World Experience from Türkiye |
| title_full | Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir/Velpatasvir/Voxilaprevir: A Multicenter Real-World Experience from Türkiye |
| title_fullStr | Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir/Velpatasvir/Voxilaprevir: A Multicenter Real-World Experience from Türkiye |
| title_full_unstemmed | Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir/Velpatasvir/Voxilaprevir: A Multicenter Real-World Experience from Türkiye |
| title_short | Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir/Velpatasvir/Voxilaprevir: A Multicenter Real-World Experience from Türkiye |
| title_sort | evaluation of treatment response in chronic hepatitis c patients receiving sofosbuvir velpatasvir voxilaprevir a multicenter real world experience from turkiye |
| topic | sofosbuvir/velpatasvir/voxilaprevir hepatitis C treatment real-world data |
| url | https://www.mdpi.com/1999-4915/17/7/931 |
| work_keys_str_mv | AT umutdevrimbinay evaluationoftreatmentresponseinchronichepatitiscpatientsreceivingsofosbuvirvelpatasvirvoxilapreviramulticenterrealworldexperiencefromturkiye AT farukkarakecili evaluationoftreatmentresponseinchronichepatitiscpatientsreceivingsofosbuvirvelpatasvirvoxilapreviramulticenterrealworldexperiencefromturkiye AT bilgehanaygen evaluationoftreatmentresponseinchronichepatitiscpatientsreceivingsofosbuvirvelpatasvirvoxilapreviramulticenterrealworldexperiencefromturkiye AT aysinkılınctoker evaluationoftreatmentresponseinchronichepatitiscpatientsreceivingsofosbuvirvelpatasvirvoxilapreviramulticenterrealworldexperiencefromturkiye AT ilhamicelik evaluationoftreatmentresponseinchronichepatitiscpatientsreceivingsofosbuvirvelpatasvirvoxilapreviramulticenterrealworldexperiencefromturkiye AT nesedemirturk evaluationoftreatmentresponseinchronichepatitiscpatientsreceivingsofosbuvirvelpatasvirvoxilapreviramulticenterrealworldexperiencefromturkiye AT tugcesimsekbozok evaluationoftreatmentresponseinchronichepatitiscpatientsreceivingsofosbuvirvelpatasvirvoxilapreviramulticenterrealworldexperiencefromturkiye AT leyladursun evaluationoftreatmentresponseinchronichepatitiscpatientsreceivingsofosbuvirvelpatasvirvoxilapreviramulticenterrealworldexperiencefromturkiye AT fethiyeakgul evaluationoftreatmentresponseinchronichepatitiscpatientsreceivingsofosbuvirvelpatasvirvoxilapreviramulticenterrealworldexperiencefromturkiye AT gulecınar evaluationoftreatmentresponseinchronichepatitiscpatientsreceivingsofosbuvirvelpatasvirvoxilapreviramulticenterrealworldexperiencefromturkiye AT ozgurgunal evaluationoftreatmentresponseinchronichepatitiscpatientsreceivingsofosbuvirvelpatasvirvoxilapreviramulticenterrealworldexperiencefromturkiye AT aliasan evaluationoftreatmentresponseinchronichepatitiscpatientsreceivingsofosbuvirvelpatasvirvoxilapreviramulticenterrealworldexperiencefromturkiye AT eyuparslan evaluationoftreatmentresponseinchronichepatitiscpatientsreceivingsofosbuvirvelpatasvirvoxilapreviramulticenterrealworldexperiencefromturkiye AT fatmayılmazkaradag evaluationoftreatmentresponseinchronichepatitiscpatientsreceivingsofosbuvirvelpatasvirvoxilapreviramulticenterrealworldexperiencefromturkiye AT orcunbarkay evaluationoftreatmentresponseinchronichepatitiscpatientsreceivingsofosbuvirvelpatasvirvoxilapreviramulticenterrealworldexperiencefromturkiye AT iremakdemir evaluationoftreatmentresponseinchronichepatitiscpatientsreceivingsofosbuvirvelpatasvirvoxilapreviramulticenterrealworldexperiencefromturkiye AT fundasimsek evaluationoftreatmentresponseinchronichepatitiscpatientsreceivingsofosbuvirvelpatasvirvoxilapreviramulticenterrealworldexperiencefromturkiye AT emineturkogluyılmaz evaluationoftreatmentresponseinchronichepatitiscpatientsreceivingsofosbuvirvelpatasvirvoxilapreviramulticenterrealworldexperiencefromturkiye AT zeynepravzaegilmez evaluationoftreatmentresponseinchronichepatitiscpatientsreceivingsofosbuvirvelpatasvirvoxilapreviramulticenterrealworldexperiencefromturkiye AT sudatekin evaluationoftreatmentresponseinchronichepatitiscpatientsreceivingsofosbuvirvelpatasvirvoxilapreviramulticenterrealworldexperiencefromturkiye AT theviralhepatitisstudygroupoftheturkishsocietyofclinicalmicrobiologyandinfectiousdiseasesklimik evaluationoftreatmentresponseinchronichepatitiscpatientsreceivingsofosbuvirvelpatasvirvoxilapreviramulticenterrealworldexperiencefromturkiye |